Rapid Degradation of Oseltamivir Phosphate in Clinical Samples by Plasma Esterases

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2006 Aug 31

PMID 16940130

Citations 16

Authors

Niklas Lindegardh

Geraint R Davies

Tinh Hien Tran

Jeremy Farrar

Pratap Singhasivanon

Nicholas P J Day

Nicholas J White

Affiliations

Soon will be listed here.

Abstract

The anti-influenza drug oseltamivir is an ester prodrug activated by hepatic carboxylesterases. Plasma esterases also convert up to 31.8% of the parent compound to the active metabolite after 4 h ex vivo, with wide interindividual variation. This source of error is removed by adding the esterase inhibitor dichlorvos to blood collection tubes.

Citing Articles

Electrochemical Acetylcholinesterase Sensors for Anti-Alzheimer's Disease Drug Determination.

Ivanov A, Shamagsumova R, Larina M, Evtugyn G Biosensors (Basel). 2024; 14(2).

PMID: 38392012 PMC: 10886970. DOI: 10.3390/bios14020093.

Metabolism and disposition of oseltamivir (OS) in rats, determined by immunohistochemistry with monospecific antibody for OS or its active metabolite oseltamivir carboxylate (OC): A possibility of transporters dividing the drugs' excretion into the....

Fujiwara K, Yamamoto Y, Saita T, Matsufuji S Pharmacol Res Perspect. 2020; 8(3):e00597.

PMID: 32489006 PMC: 7266928. DOI: 10.1002/prp2.597.

Simultaneous quantification of prodrug oseltamivir and its metabolite oseltamivir carboxylate in human plasma by LC-MS/MS to support a bioequivalence study.

Gupta A, Guttikar S, Shrivastav P, Sanyal M J Pharm Anal. 2018; 3(3):149-160.

PMID: 29403810 PMC: 5760963. DOI: 10.1016/j.jpha.2012.11.004.

Pharmacokinetic Modeling and Monte Carlo Simulation to Predict Interindividual Variability in Human Exposure to Oseltamivir and Its Active Metabolite, Ro 64-0802.

Ito M, Kusuhara H, Ose A, Kondo T, Tanabe K, Nakayama H AAPS J. 2016; 19(1):286-297.

PMID: 27800573 DOI: 10.1208/s12248-016-9992-0.

Effects of alcohol on human carboxylesterase drug metabolism.

Parker R, Hu Z, Meibohm B, Laizure S Clin Pharmacokinet. 2014; 54(6):627-38.

PMID: 25511794 PMC: 4450114. DOI: 10.1007/s40262-014-0226-2.

References

He G, Massarella J, Ward P . Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 2000; 37(6):471-84. DOI: 10.2165/00003088-199937060-00003. View

Wiltshire H, Wiltshire B, Citron A, Clarke T, Serpe C, Gray D . Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B Biomed Sci Appl. 2000; 745(2):373-88. DOI: 10.1016/s0378-4347(00)00300-5. View

Oo C, Barrett J, Hill G, Mann J, Dorr A, Dutkowski R . Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs. 2001; 3(3):229-36. DOI: 10.2165/00128072-200103030-00005. View

Lando G, Mosca A, Bonora R, Azzario F, Penco S, Marocchi A . Frequency of butyrylcholinesterase gene mutations in individuals with abnormal inhibition numbers: an Italian-population study. Pharmacogenetics. 2003; 13(5):265-70. DOI: 10.1097/00008571-200305000-00005. View

Bauld H, Gibson P, Jebson P, Brown S . Aetiology of prolonged apnoea after suxamethonium. Br J Anaesth. 1974; 46(4):273-81. DOI: 10.1093/bja/46.4.273. View

Quon C, Stampfli H . Biochemical properties of blood esmolol esterase. Drug Metab Dispos. 1985; 13(4):420-4. View

Monto A . Vaccines and antiviral drugs in pandemic preparedness. Emerg Infect Dis. 2006; 12(1):55-60. PMC: 3291404. DOI: 10.3201/eid1201.051068. View

Ward P, Small I, Smith J, Suter P, Dutkowski R . Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother. 2005; 55 Suppl 1:i5-i21. DOI: 10.1093/jac/dki018. View

L R Souza R, Mikami L, Maegawa R, Chautard-Freire-Maia E . Four new mutations in the BCHE gene of human butyrylcholinesterase in a Brazilian blood donor sample. Mol Genet Metab. 2005; 84(4):349-53. DOI: 10.1016/j.ymgme.2004.12.005. View

10.

Snell P, Dave N, Wilson K, Rowell L, Weil A, Galitz L . Lack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate. Br J Clin Pharmacol. 2005; 59(5):598-601. PMC: 1884852. DOI: 10.1111/j.1365-2125.2005.02340.x. View

11.

Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen E, Masson P . Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol. 2005; 70(11):1673-84. DOI: 10.1016/j.bcp.2005.09.002. View

12.

de Jong M, Tran T, Truong H, Vo M, Smith G, Nguyen V . Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005; 353(25):2667-72. DOI: 10.1056/NEJMoa054512. View

13.

Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A . Antivirals for influenza in healthy adults: systematic review. Lancet. 2006; 367(9507):303-13. DOI: 10.1016/S0140-6736(06)67970-1. View

14.

Jensen F, Skovgaard L, Viby-Mogensen J . Identification of human plasma cholinesterase variants in 6,688 individuals using biochemical analysis. Acta Anaesthesiol Scand. 1995; 39(2):157-62. DOI: 10.1111/j.1399-6576.1995.tb04035.x. View